MIB-626, developed by David Sinclair’s MetroBiotech, is a newer NAD booster under investigation for various health benefits. As it’s still in the early stages, it will have patent protection and could generate significant revenue for Metro. However, the research base for MIB-626 is currently sparse compared to the extensive studies on NMN.